We are actively seeking clinical research partners, principal investigators, funding organizations, and industry collaborators to bring the HUNTER Trial from protocol to publication and ultimately from first-in-human data to global market approval.
Academic medical centers, university hospitals, or research clinics with established endocrinology/diabetes departments and regulatory infrastructure (IRB, research pharmacy, data management).
Endocrinologists, clinical pharmacologists, or diabetologists with research experience seeking high-impact publication opportunities and grant funding collaborations.
Foundations, impact investors, family offices, or government agencies committed to advancing affordable, evidence-based diabetes interventions with global health equity focus.
Pharmaceutical companies, nutraceutical firms, CROs, or botanical drug developers interested in co-development, licensing, or service provision (manufacturing, regulatory, clinical operations).
120-page protocol developed to ICH-GCP standards. Statistical analysis plan pre-registered. Lifestyle intervention manuals finalized. You're funding execution, not development.
Target journals: Diabetes Care, JCEM, Lancet Diabetes Endocrinology. Co-authorship guaranteed for key collaborators. Protocol paper + primary results manuscript.
Funding partners receive first-refusal rights on Phase IIb/III co-funding and global licensing. Clear IP ownership framework. Royalty structures negotiable.
Lead investigator with 10+ years in botanical drug development. Statistical consultant with FDA submission experience. DSMB of independent experts in diabetes/clinical pharmacology.
Nagoya Protocol compliant. Royalty arrangements with West African source communities. Commitment to affordable pricing ($50/month target) for low/middle-income countries.
FDA botanical drug guidance (2016) mapped. IND application strategy developed. CMC (chemistry, manufacturing, controls) package specifications finalized. GMP manufacturing partner identified.
Access comprehensive documents detailing the HUNTER Trial protocol, budget, and partnership opportunities. Full protocol and investigator's brochure available to qualified partners upon NDA execution.
Executive summary of study design, endpoints, timeline, and eligibility criteria. Perfect for initial review by PIs and site coordinators.
Download NowLine-item budget for Phase Ib/IIa trial ($923K total). Includes personnel costs, GMP manufacturing, labs, regulatory fees, and contingency.
Request AccessAvailable to serious funding inquiries. Contact us for password.
Complete, IRB-ready protocol including statistical analysis plan, case report forms, lifestyle intervention manuals, and safety monitoring framework.
NDA RequiredAvailable to qualified PIs and institutional partners. Submit inquiry to initiate NDA.
Comprehensive reference document including phytochemistry, preclinical pharmacology/toxicology, traditional use, and dosing rationale per ICH E6(R2).
NDA RequiredEssential for PI review. Request access via partnership inquiry.
Whether you're a clinical investigator, funding organization, or industry partner, we'd love to hear from you. Submit the form below and we'll respond within 48 hours with next steps.